The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy.
MRI
Phenotype
Progressive supranuclear palsy
Vascular
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
26
06
2024
accepted:
23
08
2024
revised:
22
08
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
aheadofprint
Résumé
White matter hyperintensities (WMH) are considered magnetic brain imaging (MRI) biomarkers of cerebral small vessel disease but their clinical role in neurodegenerative-related disorders is poorly understood. This study describes the distribution of WMH on brain MRI in Progressive Supranuclear Palsy (PSP) in comparison with Parkinson's disease (PD) and explores their possible impact on disease's features. Sixty PSP and 33 PD patients were included. Motor symptoms, cardiovascular risk factors and the age-related white matter changes (ARWMC) score was computed to rate WMH for both groups. Pearson's correlation and linear or logistic regression analysis were used to check for relationships between ARWMC and PSP clinical scores. The mean (standard deviation) ARWMC total score in the PSP cohort was 4.66 (3.25). Any degree of WMH was present in 68% of PSP (ARWMC +). Compared to ARWMC-, ARWMC + did not have greater disease severity or more cardiovascular risk factors. WMH were frequently localized in fronto-parietal lobes and were mild in severity. Linear regression analysis showed that ARWMC total score was related to the PSP-rating scale, irrespective of age, disease duration and the Charlson modified comorbidity index. Logistic regression analysis confirmed that ARWMC total score was related to the use of wheelchair, irrespective of above-mentioned covariates. Vascular risk factors as well as severity and distribution of WMH did not have an impact on the PSP phenotype. No differences were found with PD patients. Our results suggest that WMH in PSP might be markers of neurodegenerative-related pathology rather than being simple expression of atherosclerotic cerebrovascular changes.
Identifiants
pubmed: 39222284
doi: 10.1007/s00415-024-12662-0
pii: 10.1007/s00415-024-12662-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Dickson DW (1999) Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 246(Suppl 2):II6-15
doi: 10.1007/BF03161076
pubmed: 10525997
Hoglinger GH, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853–64
doi: 10.1002/mds.26987
pubmed: 28467028
pmcid: 5516529
Malek N, Lawton MA, Phil M et al (2015) Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson’s disease. Mov Dis 31(10):1518–1526
doi: 10.1002/mds.26698
Shibata K, Sugiura M, Nishimura Y, Sakura H (2019) The effect of small vessel disease on motor and cognitive function in Parkinson’s disease. Clin Neurol and Neurosurg 182:58–62
doi: 10.1016/j.clineuro.2019.04.029
Moghekar A, Kraut M, Elkins W et al (2012) Cerebral white matter disease is associated with Alzheimer pathology in a prospective cohort. Alzheimers Dement 8(50):S71–S77
pubmed: 23021624
Kim HW, Hong J, Jeon JC (2020) Cerebral small vessel disease and alzheimer’s disease: a review. Front Neurol 11:927
doi: 10.3389/fneur.2020.00927
pubmed: 32982937
pmcid: 7477392
Lukic MJ, Kurz C, Respondek G et al (2020) The MDS-endorsed PSP study group. copathology in progressive supranuclear palsy: does it matter? Mov Disord 35(6):974–993
Chen X, Wang J, Shan Y et al (2018) Cerebral small vessel disease: neuroimaging markers and clinical implication. J Neurol 266(10):2347–2362
doi: 10.1007/s00415-018-9077-3
pubmed: 30291424
Wahlund LO, Barkhof F, Fazekas F et al (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32(6):1318–1322
doi: 10.1161/01.STR.32.6.1318
pubmed: 11387493
Picillo M, Cuoco S, Tepedino MF et al (2019) Motor, cognitive and behavioral differences in MDS PSP phenotypes. J Neurol 266(7):1727–1735
doi: 10.1007/s00415-019-09324-x
pubmed: 30989369
Picillo M, Erro R, Cuoco S et al (2018) MDS PSP criteria in real-life clinical setting: motor and cognitive characterization of subtypes. Mov Disord 33(8):1361–1365
doi: 10.1002/mds.27408
pubmed: 29984518
Picillo M, Tepedino MF, Abate F et al (2020) Midbrain MRI assessments in progressive supranuclear palsy subtypes. J Neurol Neurosurg Psychiatry 91(1):98–103
doi: 10.1136/jnnp-2019-321354
pubmed: 31527182
Respondek G, Höglinger GU (2016) The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 22(Suppl. 1):S34–S36
doi: 10.1016/j.parkreldis.2015.09.041
pubmed: 26421392
Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653
doi: 10.1002/mds.23429
pubmed: 21069833
Grimm M-J, Respondek G, Stamelou M et al (2019) Movement Disorder Society-endorsed PSP Study Group. how to apply the movement disorder Society criteria for diagnosis of progressive supranuclear palsy. Mov Disord 34:1228–1232
doi: 10.1002/mds.27666
pubmed: 30884545
pmcid: 6699888
Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(Pt 6):1552–1565
doi: 10.1093/brain/awm032
pubmed: 17405767
Antonini A, Abbruzzese G, Ferini-Strambi L et al (2013) Validation of the Italian version of the movement disorder society-unified Parkinson’s disease rating scale. Neurol Sci 34(5):683–687
doi: 10.1007/s10072-012-1112-z
pubmed: 22678179
Cummings JL (1997) The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurol 48(5 Suppl 6):S10–S16
Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699
doi: 10.1111/j.1532-5415.2005.53221.x
pubmed: 15817019
Diederichs CP, Wellmann J, Bartels DB et al (2012) How to weight chronic disease in multimorbidity indices? Development of a new method on the basis of individual data from live population-based studies. J Clin Epidemiol 65(6):679–685
doi: 10.1016/j.jclinepi.2011.11.006
pubmed: 22424984
Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601
doi: 10.1002/mds.26424
pubmed: 26474316
Moccia M, Tedeschi E, Ugga L et al (2016) White matter changes and the development of motor phenotypes in de novo Parkinson’s Disease. J Neurol Sci 367:215–219
doi: 10.1016/j.jns.2016.06.015
pubmed: 27423590
Kotagal V, Albin RL, Müller MLTM et al (2014) Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology 82(17):1514–1520
doi: 10.1212/WNL.0000000000000356
pubmed: 24682965
pmcid: 4011463
Rabadia SV, Litvan I, Juncos J et al (2019) ENGENE PSP study. hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord 66:166–170
doi: 10.1016/j.parkreldis.2019.07.036
pubmed: 31420308
Greten S, Wegner F, Jensen I et al (2024) The comorbidity and co-medication profile of patients with progressive supranuclear palsy. J Neurol 271(2):782–793
doi: 10.1007/s00415-023-12006-4
pubmed: 37803149
Zella MAS, Bartig D, Herrmann L et al (2020) Hospitalization rates and comorbidities in patients with progressive supranuclear palsy in Germany from 2010 to 2017. Clin Med 9(8):2454
Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S (2015) What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. Am Heart J 4:001140
Bohnen NI, Albin RL (2011) White matter lesions in Parkinson disease. Nat Rev Neurol 7(4):229–323
doi: 10.1038/nrneurol.2011.21
pubmed: 21343896
pmcid: 3739056
Danti N, Toschi SD et al (2015) Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality. Eur J Neurol 22(12):1564–1572
doi: 10.1111/ene.12785
pubmed: 26212370
Noh SW, Han NY, Mun CW et al (2014) Analysis among cognitive profiles and gray matter volume in newly diagnosed Parkinson’s disease with mild cognitive impairment. J Neurol Sci 34(1–2):210–213
doi: 10.1016/j.jns.2014.09.049
Compta Y, Buongiorno M, Bargalló N et al (2016) White matter hyperintensities, cerebrospinal amyloid-beta and dementia in Parkinson’s disease. J Neurol Sci 367:284–290
doi: 10.1016/j.jns.2016.06.009
pubmed: 27423605
Joki H, Higashiyama Y, Nakae Y et al (2018) White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson’s disease with dementia, and Alzheimer’s disease. J Neurol Sci 385:99–104
doi: 10.1016/j.jns.2017.12.018
pubmed: 29406924
Thal DR, von Arnim CAF, Griffin WST et al (2015) Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular and Alzheimer-related co-pathologies. J Neural Transm 122(7):1007–1018
doi: 10.1007/s00702-014-1360-6
pubmed: 25556950
Englund E (1998) Neuropathology of white matter changes in Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 9(Suppl 1):6–12
doi: 10.1159/000051183
pubmed: 9716238
Leys D, Pruvo JP, Parent M et al (1991) Could Wallerian degeneration contribute to “leuko-araiosis” in subjects free of any vascular disorder? J Neurol Neurosurg Psychiatry 54:46–50
doi: 10.1136/jnnp.54.1.46
pubmed: 2010759
pmcid: 1014298
Wardlaw JM, Smith EE, Biessels GJ et al (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12(8):822–838
doi: 10.1016/S1474-4422(13)70124-8
pubmed: 23867200
pmcid: 3714437